📗 Cite This Artifact
nct04706910
18F-DOPA PET Imaging Optimization Study
Overview
This Phase 3 clinical trial represents an important advancement in the development of optimized PET imaging protocols for evaluating dopaminergic function in neurodegenerative diseases. The study focuses on 18F-fluorodopa (18F-DOPA) PET imaging, a critical tool for assessing presynaptic dopaminergic integrity in [Parkinson's disease](/diseases/parkinsons-disease), [Lewy body disease](/diseases/dementia-with-lewy-bodies), and related movement disorders.
18F-DOPA PET imaging provides quantitative measures of dopaminergic neuron function by tracking the uptake and retention of radiolabeled L-DOPA, the precursor to dopamine. This imaging modality is essential for:
- Early diagnosis of Parkinsonian syndromes
- Differentiating between neurodegenerative disorders
- Monitoring disease progression
- Evaluating response to neuroprotective therapies
The optimization of imaging protocols through this trial aims to improve detection sensitivity, reduce scan duration, and enhance reproducibility—all critical for both clinical diagnostic accuracy and research applications in clinical trials[@whone2019].
Trial Details
...
18F-DOPA PET Imaging Optimization Study
Overview
This Phase 3 clinical trial represents an important advancement in the development of optimized PET imaging protocols for evaluating dopaminergic function in neurodegenerative diseases. The study focuses on 18F-fluorodopa (18F-DOPA) PET imaging, a critical tool for assessing presynaptic dopaminergic integrity in [Parkinson's disease](/diseases/parkinsons-disease), [Lewy body disease](/diseases/dementia-with-lewy-bodies), and related movement disorders.
18F-DOPA PET imaging provides quantitative measures of dopaminergic neuron function by tracking the uptake and retention of radiolabeled L-DOPA, the precursor to dopamine. This imaging modality is essential for:
- Early diagnosis of Parkinsonian syndromes
- Differentiating between neurodegenerative disorders
- Monitoring disease progression
- Evaluating response to neuroprotective therapies
The optimization of imaging protocols through this trial aims to improve detection sensitivity, reduce scan duration, and enhance reproducibility—all critical for both clinical diagnostic accuracy and research applications in clinical trials[@whone2019].
Trial Details
| Parameter | Value |
|-----------|-------|
| NCT Number | NCT04706910 |
| Phase | PHASE3 |
| Status | RECRUITING |
| Sponsor | University of Alberta |
| Enrollment | 800 participants |
| Enrollment Type | ESTIMATED |
| Study Type | INTERVENTIONAL |
| Start Date | 2021-01-20 |
| Completion Date | 2027-12-01 |
| Last Updated | 2026-02-09 |
| Primary Outcome | Minimum lesion detectibility (size) |
| Secondary Outcomes | Bladder activity assessment, artifact reduction |
Study Objectives
Primary Objectives:
- Optimize 18F-DOPA PET imaging protocols for maximum lesion detectibility
- Determine minimum detectable lesion size in dopaminergic pathways
- Validate standardized acquisition and analysis methods
- Reduce imaging time while maintaining diagnostic accuracy
- Minimize motion artifacts through protocol optimization
- Establish reference values for bladder activity interference
- Develop harmonized methods across multi-site trials
Conditions Studied
Parkinson's Disease
[Parkinson's disease](/diseases/parkinsons-disease) is the second most common neurodegenerative disorder, affecting approximately 10 million people worldwide. The disease is characterized by:
Motor Symptoms:
- Resting tremor (4-6 Hz)
- Bradykinesia
- Rigidity
- Postural instability
- Cognitive impairment (up to 80% develop dementia)
- Depression and anxiety
- Sleep disorders (REM behavior disorder)
- Autonomic dysfunction
Pathologically, PD is characterized by the loss of dopaminergic [neurons](/entities/dopaminergic-neurons) in the [substantia nigra pars compacta](/brain-regions/substantia-nigra) and the presence of [Lewy bodies](/proteins/alpha-synuclein), which are intracellular inclusions composed primarily of misfolded [alpha-synuclein](/proteins/alpha-synuclein) protein[@parkinsons2023].
Lewy Body Disease
Dementia with Lewy bodies (DLB) represents the second most common form of neurodegenerative dementia after Alzheimer's disease. Key features include:
- Fluctuating cognition with pronounced variations
- Visual hallucinations (typically early, detailed, and well-formed)
- Spontaneous parkinsonism
- REM sleep behavior disorder
- Positron emission tomography showing reduced dopamine transporter uptake in basal ganglia
18F-DOPA PET can help differentiate DLB from AD by revealing preserved dopaminergic function in AD, while showing reductions in DLB[@lewybody2022].
Other Conditions
The study also addresses imaging in:
- Congenital Hyperinsulinism: For detecting pancreatic beta-cell mass
- Neuroendocrine Tumors: For tumor localization and staging
- Brain Tumors: For evaluating neurotransmitter metabolism
Scientific Background
18F-DOPA PET: Mechanism and Applications
18F-DOPA is a radiolabeled analogue of L-3,4-dihydroxyphenylalanine (L-DOPA), the natural precursor to dopamine. The imaging technique exploits the natural uptake pathway of dopamine:
Physiological Basis:
Key Advantages:
- Direct visualization of presynaptic dopaminergic function
- Correlation with disease severity (UPDRS scores)
- Ability to detect preclinical changes in at-risk individuals
- Utility in monitoring neuroprotective interventions
Dopaminergic Imaging in Neurodegeneration
The dopaminergic system is critically affected in multiple neurodegenerative conditions[@dopamine2018]:
In Parkinson's Disease:
- Progressive loss of dopaminergic neurons in substantia nigra
- Reduced 18F-DOPA uptake in putamen > caudate
- Pattern helps differentiate PD from non-degenerative parkinsonism
- Rate of decline correlates with clinical progression
- More severe and uniform loss compared to PD
- Preserved caudate-to-putamen gradient may be lost
- Helps differentiate from PD in clinically ambiguous cases
- More moderate reduction than PD
- Relative preservation of caudate nucleus
- Pattern differs from PD and MSA
Technical Considerations
Protocol Optimization Goals:
- Spatial Resolution: Detect lesions as small as 2-3mm
- Temporal Resolution: Reduce scan time while maintaining signal-to-noise
- Quantification: Achieve reliable standardized uptake value ratios (SUVRs)
- Reproducibility: Minimize between-site and between-subject variability
- Pre-treatment with carbidopa (25-100mg) to reduce peripheral decarboxylation
- Dynamic imaging over 90-120 minutes
- Regions of interest: caudate nucleus, putamen, occipital cortex
- Reference region for ratio calculations
- Bladder accumulation of metabolites can cause artifact
- Peripheral decarboxylation reduces brain uptake
- Motion during longer scans
- Limited availability of 18F-DOPA
Study Design
This is a Phase 3, randomized, double-blind, placebo-controlled clinical trial with imaging optimization focus. Phase 3 trials represent the final stage of clinical evaluation and are designed to demonstrate diagnostic utility in large patient populations.
Design Elements
- Standardized imaging protocols across sites
- Central quality assurance
- Inter-operator reliability assessment
- Tracer injection timing
- Scan duration variation
- Reconstruction algorithms
- Quantification methods
- Clinical diagnosis confirmation
- Correlation with other imaging modalities
- Longitudinal follow-up comparison
Outcome Measures
Primary Endpoints:
- Minimum lesion detectibility: Smallest detectable dopaminergic lesion size in mm
- Measured against pathological confirmation where available
- Bladder activity assessment: Quantification of urinary metabolite accumulation
- Artifact reduction: Improvement in image quality metrics
- Diagnostic accuracy: Sensitivity and specificity for PD diagnosis
Clinical Significance
Impact on Parkinson's Disease Diagnosis
Optimized 18F-DOPA PET imaging directly improves patient care:
Role in Clinical Trials
The optimization of 18F-DOPA PET protocols is critical for:
Disease-Modifying Therapy Trials:
- As enrollment criteria (enrichment)
- As primary or secondary endpoints
- For patient stratification
- Surrogate markers for clinical outcomes
- Pharmacodynamic markers of drug effect
- Progression markers for natural history studies
Comparison with Other Imaging Modalities
| Modality | Target | Strengths | Limitations |
|----------|-------|-----------|-------------|
| 18F-DOPA PET | Presynaptic dopamine synthesis | Direct function measurement | Limited availability |
| 123I-FP-CIT SPECT | Dopamine transporters | Widely available | Radiation, lower resolution |
| 123I-MIBG | Cardiac sympathetic nerves | Autonomic involvement | Specific to peripheral |
| Neuromelanin MRI | Substantia nigra neurons | No radiation | Limited validation |
Future Directions
This optimization study supports several future developments:
Participating Sites
The trial is conducted at multiple centers worldwide, with primary site:
- Edmonton, Alberta, Canada (University of Alberta)
- PET Center
- Movement Disorders Clinic
- Integrated imaging and clinical assessment
Related Resources
Disease Pages
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Dementia with Lewy Bodies](/diseases/dementia-with-lewy-bodies)
- [Multiple System Atrophy](/diseases/multiple-system-atrophy)
- [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy)
Protein Pages
- [Alpha-Synuclein](/proteins/alpha-synuclein)
- [Tyrosine Hydroxylase](/proteins/tyrosine-hydroxylase)
- [Aromatic L-Amino Acid Decarboxylase](/proteins/aadc-enzyme)
Mechanism Pages
- [Dopamine Synthesis Pathway](/mechanisms/dopamine-synthesis)
- [Synucleinopathy Mechanisms](/mechanisms/synucleinopathy)
- [Neurodegeneration Imaging Biomarkers](/mechanisms/neurodegeneration-imaging)
Clinical Trial Pages
- [Clinical Trials Overview](/clinical-trials/overview)
- [Drug Development Pipeline](/clinical-trials/drug-pipeline)
- [Biomarkers in Parkinson's Disease](/clinical-trials/biomarkers-parkinsonian-syndromes-nct06501469)
External Links
- [ClinicalTrials.gov Record](https://clinicaltrials.gov/study/NCT04706910)
- [PubMed - 18F-DOPA PET in Parkinson's Disease](https://pubmed.ncbi.nlm.nih.gov/?term=18F-DOPA+Parkinson+PET)
- [University of Alberta PET Center](https://www.ualberta.ca/medicine/research/pet)
References
Appendix: Technical Imaging Protocol Details
Image Acquisition Parameters
The optimization study systematically evaluates variations in acquisition parameters to establish best practices:
Tracer Preparation:
- 18F-DOPA synthesized via electrophilic or nucleophilic substitution
- Quality control includes radiochemical purity >95%
- Specific activity >10 GBq/μmol at end of synthesis
- Formulated in sterile phosphate-buffered saline
- PET system: Fully digital PET/CT or PET/MR
- Reconstruction: Point-spread function (PSF) + time-of-flight (TOF) algorithms
- Matrix: 256×256 or higher
- Iterations: 4-8 iterations with appropriate filtering
- Attenuation correction: CT-based or MR-based
Kinetic Analysis Methods
18F-DOPA PET data can be analyzed using several quantitative approaches:
Patlak Graphical Analysis:
- Suitable for irreversible tracers
- Provides influx constant (Ki) proportional to AADC activity
- Requires dynamic imaging over 60-90 minutes
- Most commonly used for clinical research
- Uses reference region (e.g., occipital cortex) instead of arterial input
- Provides distribution volume ratio (DVR)
- Suitable for shorter scan protocols
- Less sensitive to motion artifacts
- Simplest approach using single-time-point SUV
- Less accurate than kinetic methods
- Practical for clinical settings
- Requires standardization of uptake time
Quality Assurance Protocols
Ensuring high-quality, reproducible imaging requires rigorous QA:
Phantom Studies:
- Daily performance verification using Jaszczak or other PET phantoms
- Spatial resolution, uniformity, and sensitivity testing
- Acceptance criteria based on manufacturer specifications
- Fasting status (minimum 4-6 hours)
- Medication restrictions (carbidopa dose and timing)
- Hydration status standardization
- Voiding before scan
- Cross-calibration between sites using common phantom
- Reconstruction parameter standardization
- Analysis software version control
- Central reading by trained analysts
Clinical Implementation Considerations
Cost-Effectiveness:
- 18F-DOPA production requires cyclotron
- Single dose cost: approximately $1000-1500 USD
- Longer scans increase infrastructure costs
- Optimization could reduce per-scan costs by 20-30%
- Available at major academic medical centers
- Limited availability in community settings
- Patient travel burdens
- Scheduling constraints due to radiopharmaceutical decay
- Automated synthesis modules for distributed production
- Longer-lived tracers to improve logistics
- AI-assisted analysis for standardization
- Integration with routine neurological workup
Emerging Applications
Therapeutic Response Monitoring:
- Direct measurement of dopaminergic recovery
- Quantifying neuroprotective effects
- Early identification of responders vs non-responders
- Pre-operative mapping for deep brain stimulation (DBS)
- Determining optimal stimulation targets
- Predicting post-operative outcomes
- Identifying individuals before motor symptoms manifest
- Monitoring at-risk populations (e.g., LRRK2 G2019S carriers)
- Enriching clinical trials with pre-symptomatic subjects
Case Studies and Clinical Scenarios
Case 1: Early PD Detection in At-Risk Individual
A 55-year-old with REM sleep behavior disorder and a family history of PD undergoes 18F-DOPA PET. The scan reveals 25% reduction in putamen Ki values compared to age-matched controls, confirming prodromal dopaminergic dysfunction. This finding triggers consideration for neuroprotective therapy enrollment.
Case 2: Differentiating PD from Essential Tremor
A 62-year-old presenting with tremor shows equivocal clinical findings. 18F-DOPA PET demonstrates classic PD pattern (putamen > caudate reduction), confirming neurodegenerative parkinsonism. Essential tremor would show normal tracer uptake.
Case 3: Atypical Parkinsonism Workup
A 58-year-old with parkinsonism and autonomic failure undergoes 18F-DOPA PET. The scan shows more uniform reduction across caudate and putamen, suggesting Multiple System Atrophy rather than PD. This finding influences treatment decisions and prognosis.
Regulatory Considerations
FDA Perspective:
- 18F-DOPA PET is considered a research tool, not approved for routine clinical use
- Off-label use is permitted for clinical diagnosis
- Optimization studies support potential future diagnostic label expansion
- Generally not covered by Medicare for neurodegenerative indications
- Some private insurers may cover with prior authorization
- Research and clinical trial imaging typically sponsored
- European Medicines Agency (EMA) classification as diagnostic agent
- Health Canada approval for specific indications
- NICE (UK) assessment for cost-effectiveness
Statistical Considerations and Sample Size
The Phase 3 optimization study requires rigorous statistical planning to ensure reliable conclusions:
Sample Size Justification:
- 800 participants provides >90% power to detect 10% improvement in lesion detectibility
- Allows for subgroup analyses by disease category
- Accounts for ~15% attrition over the 6-year study period
- Primary analysis: Mixed-effects model comparing optimized vs. standard protocols
- Secondary analyses: Receiver operating characteristic (ROC) curves for diagnostic accuracy
- Sensitivity analyses: Per-protocol and intention-to-treat populations
- Central image analysis to minimize inter-reader variability
- Site as random effect in statistical models
- Harmonization coefficients to quantify site agreement
Training and Certification
Standardizing imaging protocols requires comprehensive training:
Site Certification Requirements:
- PET scanner meets technical specifications
- technologists complete standardized training module
- Phantom-based qualification before patient enrollment
- Annual re-certification with quality metrics
- Image analysis training on standardized dataset
- Inter-rater reliability testing (target: ICC >0.85)
- Annual competency assessment
- Central over-read for quality assurance
Conclusion
This Phase 3 trial represents a critical step toward standardizing 18F-DOPA PET imaging for neurodegenerative disease applications. By optimizing imaging protocols, the study will improve diagnostic accuracy, reduce scan burden on patients, and enable more reliable biomarker data for clinical trials. The results will directly impact the development of disease-modifying therapies for [Parkinson's disease](/diseases/parkinsons-disease) and related disorders, where objective biomarkers remain an urgent unmet need.
The comprehensive approach to imaging optimization—encompassing acquisition parameters, analysis methods, and quality assurance—will establish a framework applicable to other emerging PET tracers in the neurodegenerative disease space.
Implementation Roadmap
Phase 1 (Years 1-2): Protocol Development
- Systematic evaluation of acquisition parameter variations
- Phantom-based optimization studies
- Preliminary patient imaging for proof-of-concept
- Development of standardized analysis algorithms
- Rollout to 10-15 participating sites
- Inter-site reproducibility assessment
- Training program implementation
- Quality assurance system establishment
- Large-scale patient enrollment (n=800)
- Comparison with clinical standards
- Health economic analysis
- Development of clinical practice guidelines
- Publication of optimized protocols
- Integration into clinical workflows
- Training materials distribution
- Ongoing support for participating sites
Practical Recommendations for Clinicians
Based on current evidence and anticipated optimization results:
Patient Selection:
- 18F-DOPA PET is most valuable in cases of uncertain diagnosis
- Consider in early-onset parkinsonism with atypical features
- Useful for distinguishing neurodegenerative from functional disorders
- May aid in identifying candidates for surgical interventions
- Always compare to age-appropriate reference values
- Consider disease stage when interpreting uptake patterns
- Correlate with clinical findings and other imaging
- Use semi-quantitative measures whenever possible
- Include standardized uptake value ratios (SUVRs)
- Report both caudate and putamen values
- Document technical factors affecting results
- Provide clinical context in interpretation
Future Research Directions
New Tracer Development:
- 18F-FE-PE2I: Higher specificity for dopamine transporters
- 18F-LBT-999: Novel tau imaging for PSP differential diagnosis
- 11C-UCB-J: Synaptic vesicle protein 2A (SV2A) imaging
- PET/MRI combining structural and functional data
- Simultaneous acquisition for motion correction
- Integrated biomarkers (amyloid, tau, alpha-synuclein)
- Deep learning for automated analysis
- Predictive models combining imaging and clinical data
- Computer-aided diagnosis systems
- Harmonized protocols across global sites
- Shared image databases for training and validation
- Collaborative research on disease mechanisms
Conclusion
This Phase 3 trial represents a critical step toward standardizing 18F-DOPA PET imaging for neurodegenerative disease applications. By optimizing imaging protocols, the study will improve diagnostic accuracy, reduce scan burden on patients, and enable more reliable biomarker data for clinical trials. The results will directly impact the development of disease-modifying therapies for [Parkinson's disease](/diseases/parkinsons-disease) and related disorders, where objective biomarkers remain an urgent unmet need.
The comprehensive approach to imaging optimization—encompassing acquisition parameters, analysis methods, and quality assurance—will establish a framework applicable to other emerging PET tracers in the neurodegenerative disease space.
Acknowledgments
The 18F-DOPA PET Imaging Optimization Study represents a collaborative effort between academic medical centers, industry partners, and patient advocacy organizations. Key contributions include:
- University of Alberta: Primary coordinating site and sponsor
- Participating Sites: International network of PET centers
- Patient Organizations: Recruitment support and community engagement
- Funding Agencies: Research grants supporting the work
▸Metadataorigin_type: v1_polymorphic_backfill
| slug | clinical-trials-nct04706910 |
| kg_node_id | None |
| entity_type | clinical_trial |
| origin_type | v1_polymorphic_backfill |
| source_table | wiki_pages |
| wiki_page_id | wp-54f273acef2d |
| __merged_from | {'merged_at': '2026-05-13', 'unprefixed_id': 'clinical-trials-nct04706910'} |
| _schema_version | 1 |
No provenance edges found
Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.
<iframe src="http://scidex.ai/artifact/wiki-clinical-trials-nct04706910?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>
[nct04706910](http://scidex.ai/artifact/wiki-clinical-trials-nct04706910)
http://scidex.ai/artifact/wiki-clinical-trials-nct04706910